Abiopharma

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form SCHEDULE 13G/A - InspireMD, Inc. Filed: 2025-08-11 AccNo: 0001579206-25-000008 Size: 17 KB

New Form 10-Q - Nu-Med Plus, Inc. Filed: 2025-08-11 AccNo: 0001548123-25-000047 Size: 1 MB

New Form S-8 - TG THERAPEUTICS, INC. Filed: 2025-08-08 AccNo: 0001437749-25-025753 Size: 240 KB

Kexing Biopharm geht strategische Partnerschaft mit IQVIA ein, um die globale Expansion zu beschleunigen USA - Deutsch USA - English USA - español

New Form 144 - Progyny, Inc. Filed: 2025-08-11 AccNo: 0001959173-25-005081 Size: 4 KB

New Form SCHEDULE 13G/A - Biofrontera Inc. Filed: 2025-08-11 AccNo: 0001579206-25-000007 Size: 16 KB

FDA approve DOXYCYCLINE HYCLATE

New Form 4 - ESTABLISHMENT LABS HOLDINGS INC. Filed: 2025-08-11 AccNo: 0001839059-25-000007 Size: 5 KB

FDA approve DOXYCYCLINE

FDA approve DOXYCYCLINE HYCLATE

FDA approve DOXYCYCLINE CALCIUM

New Form 8-K - ARTIVION, INC. Filed: 2025-08-11 AccNo: 0000784199-25-000136 Size: 148 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FDA approve HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE